Latest Property Portfolio News

Opthea Limited has announced a strategic pivot to develop OPT-302 for Lymphangioleiomyomatosis (LAM), a rare lung disease affecting women, aiming for ASX reinstatement in 2026. The company leverages strong intellectual property and cash reserves to pursue orphan drug designation and clinical development.

Region Group reports a $129 million uplift in its investment property portfolio valuation as of December 2025, alongside improved net tangible assets and stable gearing levels.

An independent meta-analysis presented at the ASH Annual Meeting reveals Mesoblast’s remestemcel-L achieves superior remission rates and safety outcomes compared to ruxolitinib in treating steroid-refractory acute graft-versus-host disease.

Charter Hall Retail REIT has announced a quarterly unfranked dividend of AUD 0.064 per unit, payable in February 2026, maintaining steady income for investors amid a stable retail property market.

EBR Systems has expanded its intellectual property holdings with four new patents, reinforcing its lead in wireless cardiac pacing technology, while facing a preliminary setback on a patent term extension application.

ChemX Materials Limited has emerged from voluntary administration following a Deed of Company Arrangement, while securing a significant Japanese patent for its HiPurA® High Purity Alumina process.

Recce Pharmaceuticals has secured a key patent in Hong Kong for its synthetic anti-infectives, reinforcing its intellectual property footprint in Asia and supporting its clinical and commercial ambitions in the region.

Patrys Limited has expanded its clinical pipeline by acquiring Reliis Pty Ltd, gaining a proprietary injectable formulation of Quetiapine aimed at the large and underserved delirium market. This strategic move balances Patrys’ portfolio with a near-term pharmaceutical asset alongside its biologics program.

Harvey Norman Holdings detailed its expansive international growth and omni-channel strategy at its 2025 AGM, highlighting new flagship stores and AI-driven retail innovations across eight countries.

Audeara Limited has secured a $1.22 million R&D tax incentive refund for FY25, strengthening its financial position by repaying debt and retaining non-dilutive funding to fuel ongoing product development.

Mesoblast Limited forecasts a significant jump in quarterly revenue, driven by strong sales of its FDA-approved cell therapy Ryoncil. The company’s latest update highlights robust growth and ongoing expansion in inflammatory disease treatments.

Alterity Therapeutics announces significant board changes, including the retirement of founding chairman Geoffrey Kempler and appointment of CEO Dr David Stamler as Managing Director, aligning leadership with its Phase 3 clinical ambitions.